Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

By U. Chakravarthy, Simon P. Harding, C. Rogers, S. Downes, A. Lotery, S. Wordsworth, B. Reeves. Ophthalmology (Rochester, Minn.), 2012

843 citations recorded by the source corpus.

Subfields: Epidemiology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/321359af376248891f604338a3f6b84fff7455e4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Adamis

In Ophthalmology

1. A. Adamis
2. D. Boyer
3. David M. Brown
4. N. Ferrara

Citations in the corpus

• Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. (2013, background): “Mean BCVA gain was maintained or improved through 36 months.(25) These studies also provide insights into the systemic safety of ranibizumab in separate DME populations enrolled and studied contemporaneously with RIDE and RISE.”